Compare AU
Compare IXI vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P Global 1200 Consumer Staples (IXI) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IXI | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 38 | 63 |
Median incremental investment | $996.75 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,228.40 | $1,905.75 |
Average age group | > 35 | 26 - 35 |
Key Summary
IXI | DRUG | |
|---|---|---|
Strategy | IXI.AX was created on 2006-09-12 by iShares. The fund's investment portfolio concentrates primarily on consumer staples equity. The fund aims to provide investors with the performance of the S&P Global 1200 Consumer Staples Sector Index, before fees and expenses. The index is designed to measure the performance of global consumer staples companies and may include large-, mid- or smallcapitalisation stocks. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | ISHARES GLOBAL CONSUMER STAPLES ET (99.97 %) USD CASH (0.21 %) USD/AUD (0.00 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (99.92 %) Communication Services (0.08 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (62.00 %) United Kingdom of Great Britain and Northern Ireland (12.09 %) Japan (5.56 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.4 % | 0.57 % |
Key Summary
IXI | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | S&P Global 1200 / Consumer Staples -SEC | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.57 % |
Price | $99.04 | $8.25 |
Size | $136.890 million | $182.401 million |
10Y return | 81.23 % | N/A |
Annual distribution yield (5Y) | 2.18 % | 1.90 % |
Market | ASX | ASX |
First listed date | 11/03/2009 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IXI | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 38 | 63 |
Median incremental investment | $996.75 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,228.40 | $1,905.75 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
IXI | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IXI | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |